KAM
FOLD

Kazazian Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Kazazian Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-18,053
Closed -$173K – 65
2018
Q4 		$173K Buy
18,053
+2,081
+13% +$22.9K 0.23% 56
2018
Q3 		$193K Buy
+15,972
New +$223K 0.18% 82

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Kazazian Asset Management's FOLD Position: Q1 2019 in Review

Kazazian Asset Management sold out of Amicus Therapeutics (FOLD) in Q1 2019, closing a stake of 18,053 shares — an estimated $173K sold.

Kazazian Asset Management first reported a position in FOLD in Q3 2018 and held it in 2 quarters. The position peaked at $193K in Q3 2018. 205 funds tracked by Wall St. Rank hold FOLD as of Q1 2019.

  • Kazazian Asset Management reported no remaining Amicus Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Kazazian Asset Management sold 18,053 Amicus Therapeutics shares in Q1 2019, an estimated $173K.
  • Kazazian Asset Management first reported a position in Amicus Therapeutics in Q3 2018 and held it in 2 quarters.
  • Kazazian Asset Management's Amicus Therapeutics position peaked at $193K in Q3 2018.
  • 205 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2019.

Based on Kazazian Asset Management's 13F filing for Q1 2019, filed 15 May 2019.